skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Gastrin receptor-avid peptide conjugates

Patent ·
OSTI ID:1175787

A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.

Research Organization:
Univ. of Missouri, Columbia, MO (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
FG02-89ER60875
Assignee:
University Of Missouri
Patent Number(s):
7,060,247
Application Number:
09/847,134
OSTI ID:
1175787
Country of Publication:
United States
Language:
English

References (27)

The Design of Site-Directed Radiopharmaceuticals for Use in Drug Discovery book January 1993
Potent Gastrin-Releasing Peptide (GRP) Antagonists Derived from GRP(19-27) with a C-Terminal DPro.PSI.[CH2NH]Phe-NH2 and N-Terminal Aromatic Residues journal February 1994
BW2258U89: A GRP receptor antagonist which inhibits small cell lung cancer growth journal January 1995
Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists journal March 1992
Synthesis, Characterization, and Labeling with 99m Tc/ 188 Re of Peptide Conjugates Containing a Dithia-bisphosphine Chelating Agent journal May 2001
Chemical and physical properties of radionuclides journal January 1987
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy journal April 1997
Vehicles, Chelators, and Radionuclides:  Choosing the “Building Blocks” of an Effective Therapeutic Radioimmunoconjugate journal January 1996
Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: A new gastrin releasing peptide receptor (GRPr) targeting radiopharma ceutical journal May 2001
Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi journal March 1992
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives. journal December 1994
Peptides in Oncology II book January 1993
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors journal September 1994
In vitro and in vivo characterization of novel water-soluble dithio-bisphosphine 99mTc complexes journal October 1997
The mechanism of receptor-mediated endocytosis journal December 1991
Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems journal March 1995
Rhenium(V) and Technetium(V) Oxo Complexes of an N 2 N‘S Peptidic Chelator:  Evidence of Interconversion between the Syn and Anti Conformations journal December 1997
Development of an in vitro model for assessing the in vivo stability of lanthanide chelates journal February 2001
Comparisons of 105Rh(III) Chloride Complexation with [14]aneNS3, [14]aneN2S2 and [14]aneN4 Macrocycles in Aqueous Solution journal January 1996
BW1023U90: A new GRP receptor antagonist for small-cell lung cancer cells journal January 1996
Binding, internalization, and processing of bombesin by rat pancreatic acini journal July 1991
No carrier added preparations of ‘3 + 1’ mixed-ligand 99mTc complexes journal January 1998
Pharmacokinetics of Antibodies and their Radiolabels book January 2018
Functional Targets book January 1996
Tumour targeting with radiolabelled macrocycle–antibody conjugates journal January 1990
Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: Internalization of receptor bound125I-(Tyr4) bombesin by tumor cells journal July 1994
Design and development of receptor-avid peptide conjugates for in-vivo targeting of cancer conference July 1999

Similar Records

Gastrin Receptor-Avid Peptide Conjugates
Patent · Tue Jul 26 00:00:00 EDT 2005 · OSTI ID:1175787

Gastrin receptor-avid peptide conjugates
Patent · Tue Dec 12 00:00:00 EST 2006 · OSTI ID:1175787

Gastrin receptor-avid peptide conjugates
Patent · Mon Jan 01 00:00:00 EST 2001 · OSTI ID:1175787